EP2588106A4 - Sustained-release pharmaceutical composition containing pramipexole or pharmaceutically acceptable salt thereof with improved stability - Google Patents

Sustained-release pharmaceutical composition containing pramipexole or pharmaceutically acceptable salt thereof with improved stability

Info

Publication number
EP2588106A4
EP2588106A4 EP11801051.1A EP11801051A EP2588106A4 EP 2588106 A4 EP2588106 A4 EP 2588106A4 EP 11801051 A EP11801051 A EP 11801051A EP 2588106 A4 EP2588106 A4 EP 2588106A4
Authority
EP
European Patent Office
Prior art keywords
sustained
pharmaceutically acceptable
pharmaceutical composition
acceptable salt
composition containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11801051.1A
Other languages
German (de)
French (fr)
Other versions
EP2588106A2 (en
Inventor
Sang-Joon Lee
Kwan-Young Chang
Jae-Soon Ahn
Jae-Min Cho
Sung-Hoon Kam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hyundai Pharm Co Ltd
Original Assignee
Hyundai Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hyundai Pharm Co Ltd filed Critical Hyundai Pharm Co Ltd
Publication of EP2588106A2 publication Critical patent/EP2588106A2/en
Publication of EP2588106A4 publication Critical patent/EP2588106A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP11801051.1A 2010-07-02 2011-05-12 Sustained-release pharmaceutical composition containing pramipexole or pharmaceutically acceptable salt thereof with improved stability Withdrawn EP2588106A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020100064044A KR101307334B1 (en) 2010-07-02 2010-07-02 Sustained-release pharmaceutical composition comprising pramipexole or pharmaceutically acceptable salt thereof having improved stability
PCT/KR2011/003515 WO2012002644A2 (en) 2010-07-02 2011-05-12 Sustained-release pharmaceutical composition containing pramipexole or pharmaceutically acceptable salt thereof with improved stability

Publications (2)

Publication Number Publication Date
EP2588106A2 EP2588106A2 (en) 2013-05-08
EP2588106A4 true EP2588106A4 (en) 2014-01-01

Family

ID=45402507

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11801051.1A Withdrawn EP2588106A4 (en) 2010-07-02 2011-05-12 Sustained-release pharmaceutical composition containing pramipexole or pharmaceutically acceptable salt thereof with improved stability

Country Status (4)

Country Link
EP (1) EP2588106A4 (en)
JP (1) JP2013530212A (en)
KR (1) KR101307334B1 (en)
WO (1) WO2012002644A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2529984C (en) 2003-06-26 2012-09-25 Isa Odidi Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
CN104825397A (en) 2006-04-03 2015-08-12 伊萨·奥迪迪 Controlled release delivery device comprising an organosol coat
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
EP2906202A4 (en) * 2012-10-15 2016-04-27 Isa Odidi Oral drug delivery formulations
CN105456216B (en) * 2014-08-18 2019-11-05 江苏神龙药业股份有限公司 Pramipexole hydrochloride slow release tablet composition and preparation method thereof
CN106474084B (en) * 2015-08-28 2020-12-11 江苏先声药业有限公司 Pramipexole dihydrochloride sustained-release preparation and preparation method thereof
CN107951853B (en) * 2016-10-17 2022-04-08 海思科制药(眉山)有限公司 Pramipexole dihydrochloride sustained-release pharmaceutical composition and preparation method thereof
CN108785263B (en) * 2017-04-26 2021-06-29 江苏恒瑞医药股份有限公司 Solid pharmaceutical composition of pramipexole or pharmaceutical salt thereof and preparation method thereof
CN114939112B (en) * 2017-12-28 2024-03-01 北京北大维信生物科技有限公司 Pramipexole sustained-release pharmaceutical composition, preparation method and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0428038A2 (en) * 1989-11-09 1991-05-22 Boehringer Ingelheim Kg Transdermal application of 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
WO2007002518A1 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Delayed release or extended-delayed release dosage forms of pramipexole
WO2007054976A2 (en) * 2005-11-08 2007-05-18 Panacea Biotec Ltd. Lipid based controlled release pharmaceutical composition
WO2009152041A2 (en) * 2008-06-09 2009-12-17 Supernus Pharmaceuticals, Inc. Controlled release formulations of pramipexole
WO2011037976A2 (en) * 2009-09-22 2011-03-31 Dr. Reddy's Laboratories Limited Pramipexole pharmaceutical formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
EP1526843A1 (en) * 2002-07-25 2005-05-04 Pharmacia Corporation Method of preparing solid dosage forms coated in two layers comprising a water-insoluble polymer and a water-soluble pore former
EP2431027A1 (en) * 2004-08-13 2012-03-21 Boehringer Ingelheim International GmbH Extended release pellet formulation containing Pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
WO2006046256A1 (en) 2004-10-27 2006-05-04 Alembic Limited Extended release formulation of pramipexole dihydrochloride
WO2007090882A2 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Pharmaceutical extended release compositions comprising pramipexole
WO2008068778A2 (en) 2006-12-05 2008-06-12 Alembic Limited Extended release pharmaceutical composition of pramipexole

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0428038A2 (en) * 1989-11-09 1991-05-22 Boehringer Ingelheim Kg Transdermal application of 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
WO2007002518A1 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Delayed release or extended-delayed release dosage forms of pramipexole
WO2007054976A2 (en) * 2005-11-08 2007-05-18 Panacea Biotec Ltd. Lipid based controlled release pharmaceutical composition
WO2009152041A2 (en) * 2008-06-09 2009-12-17 Supernus Pharmaceuticals, Inc. Controlled release formulations of pramipexole
WO2011037976A2 (en) * 2009-09-22 2011-03-31 Dr. Reddy's Laboratories Limited Pramipexole pharmaceutical formulations

Also Published As

Publication number Publication date
KR101307334B1 (en) 2013-09-12
WO2012002644A2 (en) 2012-01-05
KR20120003278A (en) 2012-01-10
EP2588106A2 (en) 2013-05-08
WO2012002644A3 (en) 2012-04-12
JP2013530212A (en) 2013-07-25

Similar Documents

Publication Publication Date Title
IL259921B (en) New stabilizing agent for pharmaceutical proteins
EP2588106A4 (en) Sustained-release pharmaceutical composition containing pramipexole or pharmaceutically acceptable salt thereof with improved stability
HK1246170A1 (en) Pharmaceutical composition
HU1000069D0 (en) New salts for the preparation of pharmaceutical composition
HRP20181170T1 (en) Novel cephalosporin derivative and pharmaceutical composition thereof
EP2604260A4 (en) Novel heterocyclic derivatives and pharmaceutical composition containing same
PL2619182T3 (en) Pharmaceutical composition
HK1181389A1 (en) Pharmaceutical composition comprising amide derivative or pharmaceutically acceptable salt thereof
ZA201207375B (en) Stabilized pharmaceutical composition
HRP20160901T1 (en) Pharmaceutical composition containing solifenacin
IL230907A0 (en) Salt and polymorph of pyrazolopyrimidinone compound, and pharmaceutical composition containing the same, preparation method and use thereof
EP2386301A4 (en) Pharmaceutical composition of levoamlodipine or pharmaceutically acceptable salts thereof and b blockers, and use thereof
GB201001911D0 (en) Pharmaceutical composition
IL238071B (en) Pharmaceutical composition of 1-adamantylethyloxy-3-morpholino-2-propanol or pharmaceutically acceptable salts thereof for the treatment of cardiovascular disease
EP2789613A4 (en) 1, 4-dihydro-naphthyridine derivative and pharmaceutical composition and use thereof
EP2543373A4 (en) Compound pharmaceutical composition of levoamlodipine
EP2628488A4 (en) Sustained-release pharmaceutical composition
HU1000006D0 (en) Improved pharmaceutical composition
GB201020364D0 (en) Pharmaceutical compounds
GB201020366D0 (en) Pharmaceutical compounds
GB201013968D0 (en) Pharmaceutical compounds
GB201001216D0 (en) Pharmaceutical compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130114

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20131204

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/38 20060101ALI20131128BHEP

Ipc: A61K 9/20 20060101ALI20131128BHEP

Ipc: A61K 9/22 20060101ALI20131128BHEP

Ipc: A61K 31/425 20060101AFI20131128BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140701